PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm

Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma

(2019) Sylvie Lantuejoul et al.   Journal of Thoracic Disease

Genomic correlates of response to immune checkpoint blockade

(2019) Tanya E. Keenan et al.   NATURE MEDICINE

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm

(2019) Naveen Pemmaraju et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations

(2018) Ioannis Zerdes et al.   ONCOGENE

Immunomodulatory bonds of the partnership between dendritic cells and T cells

(2018) Daniel Hawiger et al.   CRITICAL REVIEWS IN IMMUNOLOGY

Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm

(2018) Guru Subramanian Guru Murthy et al.   LEUKEMIA RESEARCH

Blastic Plasmacytoid Dendritic Cell Neoplasm

(2018) Joseph D. Khoury   Current Hematologic Malignancy Reports

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma

(2018) Tomas Jelinek et al.   Frontiers in Immunology

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

(2017) Mizuki Nishino et al.   Nature Reviews Clinical Oncology

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

(2016) Sara Gandini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 expression in human cancers and its association with clinical outcomes

(2016) Jinming Yu et al.   OncoTargets and Therapy

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 and Survival in Solid Tumors: A Meta-Analysis

(2015) Pin Wu et al.   PLoS One

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy

(2015) Anne-Marit Sponaas et al.   PLoS One

BRAFkinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-typeRAS

(2014) Liping Zhang et al.   AMERICAN JOURNAL OF HEMATOLOGY

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

(2014) A. E. Frankel et al.   BLOOD

TET2mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow

(2013) Khaled Alayed et al.   AMERICAN JOURNAL OF HEMATOLOGY

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study

(2013) L. Pagano et al.   HAEMATOLOGICA

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: Results from the Hellenic Dendritic Cell Leukemia Study Group

(2009) Nikolaos J. Tsagarakis et al.   LEUKEMIA RESEARCH